Kiora Asset Turnover vs Operating Income Analysis
KPRX Stock | USD 0.51 0.04 7.27% |
Kiora Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Kiora Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kiora Pharmaceuticals is a good investment. Please check the relationship between Kiora Pharmaceuticals Asset Turnover and its Operating Income accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.
Asset Turnover vs Operating Income
Asset Turnover vs Operating Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kiora Pharmaceuticals Asset Turnover account and Operating Income. At this time, the significance of the direction appears to have weak relationship.
The correlation between Kiora Pharmaceuticals' Asset Turnover and Operating Income is 0.32. Overlapping area represents the amount of variation of Asset Turnover that can explain the historical movement of Operating Income in the same time period over historical financial statements of Kiora Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Kiora Pharmaceuticals' Asset Turnover and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Asset Turnover of Kiora Pharmaceuticals are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Asset Turnover i.e., Kiora Pharmaceuticals' Asset Turnover and Operating Income go up and down completely randomly.
Correlation Coefficient | 0.32 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Asset Turnover
The ratio of net sales to average total assets, indicating how efficiently a company uses its assets to generate sales.Operating Income
Operating Income is the amount of profit realized from Kiora Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Kiora Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most indicators from Kiora Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kiora Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.At this time, Kiora Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 94.8 K in 2024, whereas Enterprise Value Over EBITDA is likely to drop (0.02) in 2024.
Kiora Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Kiora Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Kiora Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 10.1M | 15.2M | 18.1M | 18.7M | 13.7M | 11.7M | |
Short Long Term Debt Total | 83.9K | 362.1K | 209.4K | 105.8K | 106.9K | 101.5K | |
Other Current Liab | 1.1M | 1.3M | 1.3M | 2.2M | 1.4M | 1.3M | |
Total Current Liabilities | 1.4M | 1.8M | 1.6M | 3.3M | 1.6M | 3.2M | |
Total Stockholder Equity | 6.6M | 7.0M | 9.2M | 11.4M | 6.1M | 6.4M | |
Property Plant And Equipment Net | 16.8K | 30.6K | 283.4K | 172.2K | 115.0K | 76.8K | |
Net Debt | (3.7M) | (823.6K) | (7.6M) | (5.9M) | (2.3M) | (2.5M) | |
Retained Earnings | (100.2M) | (108.3M) | (124.7M) | (134.5M) | (147.0M) | (154.3M) | |
Accounts Payable | 210.3K | 434.8K | 160.6K | 1.0M | 206.3K | 195.9K | |
Cash | 3.8M | 1.2M | 7.9M | 6.0M | 2.5M | 4.7M | |
Non Current Assets Total | 5.8M | 13.3M | 9.1M | 11.0M | 9.0M | 6.1M | |
Non Currrent Assets Other | 114.4K | 102.1K | 88.0K | 82.3K | 40.8K | 38.7K | |
Cash And Short Term Investments | 3.8M | 1.2M | 7.9M | 6.0M | 2.5M | 4.7M | |
Net Receivables | 4.9K | 91.0K | 529.6K | 1.4M | 2.0M | 2.2M | |
Common Stock Shares Outstanding | 79.5K | 114.8K | 241.1K | 732.3K | 4.8M | 5.1M | |
Liabilities And Stockholders Equity | 10.1M | 15.2M | 18.1M | 18.7M | 13.7M | 11.7M | |
Non Current Liabilities Total | 2.1M | 6.4M | 7.2M | 4.0M | 6.0M | 10.2M | |
Other Current Assets | 542.7K | 533.5K | 606.5K | 343.1K | 233.4K | 368.7K | |
Other Stockholder Equity | 106.7M | 115.3M | 133.9M | 146.0M | 153.2M | 93.1M | |
Total Liab | 3.5M | 8.2M | 8.8M | 7.3M | 7.6M | 12.5M | |
Total Current Assets | 4.3M | 1.8M | 9.0M | 7.7M | 4.7M | 5.6M | |
Accumulated Other Comprehensive Income | 139.5K | (802.0) | (86.4K) | (182.7K) | (182.8K) | (173.7K) | |
Short Term Debt | 83.9K | 48.3K | 118.8K | 105.8K | 47.1K | 44.7K | |
Common Stock | 40.8K | 55.6K | 126.6K | 18.0K | 77.1K | 101.9K | |
Intangible Assets | 4.1M | 9.7M | 8.7M | 10.7M | 8.8M | 7.9M | |
Other Liab | 1.5M | 2.1M | 6.1M | 7.1M | 8.2M | 8.6M | |
Net Tangible Assets | 7.2M | 4.9M | 3.3M | 9.1M | 10.4M | 10.9M | |
Capital Lease Obligations | 83.9K | 83.9K | 209.4K | 105.8K | 106.9K | 96.0K | |
Net Invested Capital | 6.6M | 7.3M | 9.2M | 11.4M | 6.1M | 7.5M | |
Non Current Liabilities Other | 1.7M | 5.3M | 6.5M | 3.3M | 5.1M | 3.8M | |
Net Working Capital | 2.9M | 37.8K | 7.4M | 4.4M | 3.1M | 2.5M | |
Property Plant Equipment | 43.5K | 16.8K | 30.6K | 283.4K | 325.9K | 342.2K | |
Capital Stock | 40.8K | 55.6K | 126.6K | 18.0K | 77.1K | 100.8K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kiora Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kiora Pharmaceuticals' short interest history, or implied volatility extrapolated from Kiora Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Kiora Stock analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is Kiora Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiora Pharmaceuticals. If investors know Kiora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiora Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.69) | Revenue Per Share 0.002 | Return On Assets (0.34) | Return On Equity (1.43) |
The market value of Kiora Pharmaceuticals is measured differently than its book value, which is the value of Kiora that is recorded on the company's balance sheet. Investors also form their own opinion of Kiora Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiora Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiora Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiora Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiora Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiora Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiora Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.